JAK inhibition in a kidney transplant recipient with primary myelofibrosis (TTS 2026) - Sep 17, 2026 - Abstract #P1.117; Pres time: Sep 21, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P1; "Induction immunosuppression included basiliximab and methylprednisolone, followed by maintenance tacrolimus and mycophenolate mofetil, with dose reduction due to PMF...Subsequently, the patient developed biopsy-proven allograft rejection leading to ruxolitinib discontinuation and transition to the second-generation JAK inhibitor, fedratinib... This case illustrates the complexity of managing concurrent JAK inhibitor therapy and transplant immunosuppression. As JAK inhibitors become more widely used, careful titration of overall immunosuppressive burden, multidisciplinary collaboration, and close virological and graft monitoring will be increasingly important. Whilst further experience is needed to guide their safe use in transplant recipients."
Clinical • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Myelofibrosis • Nephrology • Solid Organ Transplantation • Transplant Rejection • Transplantation
|
|
Laura Bywater1; Justin Gill2; David Nicholl2
|